Forgot Password?
Return to Course Listing

CME: Targeting chronic lymphocytic leukemia (CLL): Approaches to care at different stages of the disease - Updates from ASCO 2023

ACCREDITATION EXPIRED: July 24, 2024

Activity Description / Statement of Need:

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a diverse group of hematologic cancers in which B-cells accumulate in the blood, bone marrow, and lymphatic tissue, constituting as absolute lymphocytosis of mature-appearing lymphocytes with an appropriate immunophenotype. Elderly patients comprise the vast majority of those diagnosed with CLL with a median patient age of 71 years. Men have close to twice the risk of women of developing CLL, and there are over 20,000 cases per year, with an annual mortality rate in excess of 4,400.

Target Audience:

HCPs including: Medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.


Commercial Support Disclosure: This program is supported by an educational grant from Merck.

This activity is free of charge.


Release Date: July 24, 2023 -- Expiration Date: July 24, 2024

Faculty: Christine E. Ryan, MD

Agenda

Introduction, disclosures, overview of CLL 

Major findings from ASCO 2023, including clinical trial data  relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content) 

Predicted of applicability to clinical practice and patient cases, where relevant 

Concluding remarks 

Learning Objectives

By the end of the session the participant will be able to:

  • Recognize key components of CLL diagnosis and indications for treatment
  • Recall the 3 preferred CLL/SLL first-line regimens per NCCN Guidelines and apply that information to a patient case
  • Summarize treatment considerations for elderly patients with CLL/SLL and recently reported results of the Alliance A041702 Study
  • Describe data supporting new therapies for relapsed/refractory CLL/SLL presented at ASCO 2023

Accreditation

ACCME Activity #202540660

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Christine E. Ryan, MD, Clinical Fellow in Hematology/Oncology, Dana‐Farber Cancer Institute, Harvard, received honorarium from Research To Practice and Curio Science. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

Myeloma bone disease: Monitoring and management

Acute hepatic porphyria: optimizing pharmacotherapeutic management strategies

The spectrum of alpha-thalassemia: comprehensive care of an orphan disease